Novartis names new US pharma chief

Share this article:
Novartis confirmed in published reports today that it has appointed Ludwig Hantson to head its US pharmaceuticals business. 

Hantson reports to Joe Jimenez, CEO of the Basel, Switzerland-based company's pharmaceutical business. Hantson replaces Alex Gorsky, who announced he was leaving Novartis in February. 
Hantson most recently served as head of Novartis' specialty pharmaceuticals unit in the US, where he has worked since December 2006. 

Novartis also said Paulo Costa, president and CEO of Novartis' US unit, will retire June 30 and be replaced by Gary Rosenthal. Rosenthal is currently CFO of the US pharmaceuticals business. 
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...